Related Experiment Video
Updated: Feb 23, 2026

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells
Published on: March 10, 2023
Integrating Vectors for Gene Therapy and Clonal Tracking of Engineered Hematopoiesis
Luca Biasco1, Michael Rothe2, Juliane W Schott2
1Gene Therapy Program, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, 1 Jimmy Fund Way, Boston, MA 02115, USA; University College London, UCL Great Ormond Street Institute of Child Health, UCL Faculty of Population Health Sciences, 30 Guilford Street, London WC1N 1EH, UK.
Abstract:
Gene therapy using autologous or allogeneic cells offers promising possibilities to treat inherited and acquired diseases, ideally leading to a long-lasting therapeutic correction. This article summarizes efforts that use integrating vectors derived from retroviruses and transposons, and briefly explains integrating vector biology and integration site analysis and recent successful application of this technology in clinical trials. Moreover, outlined is how these vectors can be used for cancer gene discovery and clonal tracking of benign and malignant hematopoiesis to gain insights into the dynamics of hematopoiesis.

